Jasmiel 28 Day Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed Jasmiel 28 Day (drospirenone 3 mg / ethinyl estradiol 0.02 mg) may periodically report difficulty obtaining their prescription at local pharmacies. This guide provides prescribers and clinical staff with current supply status, therapeutic substitution options, and patient management strategies.

Current Supply Status

As of 2026, Jasmiel 28 Day is not listed on the FDA Drug Shortages Database. Afaxys Pharma, LLC — the manufacturer — has not reported a formal supply disruption. However, prescribers should be aware that the generic oral contraceptive market involves multiple manufacturers competing for formulary placement, meaning individual pharmacies may stock one Yaz generic preferentially over others. Patient-reported stock gaps are largely localized, not indicative of a nationwide shortage.

Pharmacology and Formulation Overview

Jasmiel 28 Day is a 24/4 monophasic combination oral contraceptive containing:

• Drospirenone (DRSP) 3 mg: A spironolactone analogue with anti-mineralocorticoid and antiandrogenic properties. May raise serum potassium, particularly relevant in patients on ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, or heparin.
• Ethinyl estradiol (EE) 0.02 mg: Low-dose estrogen. Studies show >90% ovulation inhibition with the 24/4 regimen, which offers tighter hormonal control than a traditional 21/7 schedule.

FDA-approved indications include: contraception, PMDD (in patients choosing OC for contraception), and moderate acne in females ≥14 years choosing OC for contraception.

Therapeutic Substitution Options

The following substitution tiers can guide clinical decision-making when Jasmiel is unavailable:

Tier 1: Direct AB-Rated Equivalents (No New Prescription Required in Most States)

• Loryna 28 Day (drospirenone 3 mg / EE 0.02 mg)
• Nikki 28 Day (drospirenone 3 mg / EE 0.02 mg)
• Gianvi (drospirenone 3 mg / EE 0.02 mg)
• Lo-Zumandimine 28 Day (drospirenone 3 mg / EE 0.02 mg)
• Vestura (drospirenone 3 mg / EE 0.02 mg)
• Yaz (drospirenone 3 mg / EE 0.02 mg — brand name)

Tier 2: Same Progestin, Higher EE Dose (New Prescription Required)

Yasmin and its generics (Ocella, Syeda, Zumandimine) contain drospirenone 3 mg / EE 0.03 mg, with a 21/7 regimen. Note these are approved only for contraception — not PMDD or acne. Beyaz adds levomefolate calcium 0.45 mg to the same formulation as Yaz and retains all three indications.

Tier 3: Different Progestin Class (New Prescription Required)

If switching away from drospirenone is clinically indicated (e.g., VTE risk concerns, hyperkalemia risk, renal impairment), consider:

• Norgestimate/EE (Sprintec, Ortho Tri-Cyclen): FDA-approved for contraception and acne; widely available
• Levonorgestrel/EE (Levora, Portia): Lower VTE risk profile than DRSP-containing COCs per available data
• Norethindrone acetate/EE (Junel Fe, Loestrin): Established tolerability profile, widely available generics

Important Prescribing Considerations When Substituting

• PMDD indication: Only Yaz/Jasmiel-class (3 mg DRSP / 0.02 mg EE, 24/4 schedule) is FDA-approved for PMDD. Yasmin generics and Tier 3 alternatives are not approved for PMDD.
• Acne indication: Yaz generics (Tier 1), Beyaz, Ortho Tri-Cyclen/Sprintec (norgestimate), and Estrostep Fe (norethindrone acetate/EE) are FDA-approved for acne. Yasmin generics are NOT.
• Potassium monitoring: DRSP's antimineralocorticoid activity can increase serum potassium. If the patient uses potassium-elevating medications, confirm serum potassium during the first treatment cycle.
• Contraindications for the entire class: Renal impairment, hepatic impairment, adrenal insufficiency, uncontrolled hypertension, thrombophilia, smoking + age >35, and concurrent HCV therapy with ombitasvir/paritaprevir/ritonavir.

Helping Your Patients Find Jasmiel 28 Day

If patients continue to have difficulty finding Jasmiel, recommend medfinder for providers — a service that calls pharmacies near your patient's location to identify which ones have the medication in stock. This reduces time spent on follow-up calls and helps patients maintain uninterrupted contraceptive coverage. See our full provider guide: How to Help Your Patients Find Jasmiel 28 Day in Stock.

Patient Counseling Points When Jasmiel Is Unavailable

• Instruct patients on backup contraception (condoms + spermicide) if there is any gap between pill packs
• Clarify that equivalent generics (Loryna, Nikki, Gianvi) have the same active ingredients and same clinical effects
• Reinforce that switching within the same Tier 1 group does NOT require starting a new pill cycle from day 1 — they continue from where they are
• For patients on Jasmiel for PMDD: ensure any substitution remains within the 24/4 DRSP 3 mg / EE 0.02 mg class to preserve the PMDD indication